Brokerage Notes & Targets: Colgate-Palmolive India Ltd and Laurus Labs Ltd
In this post, we analyse two stocks in focus — FMCG major Colgate-Palmolive India Ltd and pharma/biotech play Laurus Labs Ltd. We will detail recent results, decode key financial jargon for the layman, summarise brokerage commentary & target prices, compare with peers, and arrive at an actionable verdict: whether to invest, wait or avoid.
1. Colgate-Palmolive India Ltd (Ticker: “Colgate India”)
Recent results & context: The company reported for Q2 FY26 a net profit of ₹ 327.51 crore, down from ₹ 395.05 crore a year ago. Revenue from operations stood at ~₹ 1,507 crore versus ~₹ 1,609 crore last year — a decline of ~6.3% YoY. The company cited headwinds such as the drop in GST on oral-care products (from 18% to 5%), which caused sales disruption, and weak urban demand.
Key jargon explained for layman:
- Volumes: How many units of product are sold. A negative volume means fewer units sold which affects revenue even if price remains same.
- Margin expansion / contraction: Margin = (Profit ÷ Sales). If sales fall but costs fall faster then margin may increase; but if volumes fall significantly, operating leverage suffers (fixed costs spread over fewer units) so margin may shrink.
- Operating leverage: The benefit a company gets when fixed costs are spread over higher sales volume. If volumes fall then operating leverage works against the company.
Quantified snapshot:
| Metric | Q2 FY26 | Q2 FY25 | YoY Change |
|---|---|---|---|
| Revenue from Operations | ₹ 1,507 crore | ₹ 1,609 crore | ↓ 6.3% |
| Net Profit (PAT) | ₹ 327.5 crore | ₹ 395.0 crore | ↓ 17% |
| Volume Growth | -8.5% | +2.3% | Negative volume growth due to GST disruption |
Brokerage commentary & target prices:
| Broker | Rating | Target Price (₹) | Comment |
|---|---|---|---|
| CLSA | Hold | 2,130 | Q2 miss; sales -6.3% YoY; margin expansion offset by lower sales |
| Nomura | Reduce | 2,200 | Volumes -8.5% YoY; negative operating leverage |
| Nuvama | Buy | 2,870 | Q2 weak; EBITDA margin flat; toothpaste volume -4% YoY |
| Investec | Sell | 1,800 | Innovation & premiumisation failing; valuation high |
| Jefferies | Sell | 2,279 | Revenue falls on GST impact; EBITDA under pressure |
Investment verdict for Colgate India: Given the top-line decline, structural headwinds and mixed broker opinions, the stock appears cautious. Verdict: Hold / Skip for now.
2. Laurus Labs Ltd (Ticker: “Laurus Labs”)
Recent performance: The company reported Q2 FY26 revenue of ₹ 1,653 crore, up ~35% YoY. Net profit surged ~875% YoY to ₹ 195 crore. EBITDA rose ~136% YoY to ₹ 429 crore and margin expanded to ~26% (from ~15%).
Quantified snapshot:
| Metric | Q2 FY26 | Q2 FY25 | YoY Change |
|---|---|---|---|
| Revenue from Operations | ₹ 1,653 crore | ₹ 1,224 crore | ↑ 35% |
| EBITDA | ₹ 429 crore | ₹ 182 crore | ↑ 136% |
| EBITDA Margin | 26% | 15% | ↑ Margin expansion |
| Net Profit (PAT) | ₹ 195 crore | ₹ 20 crore | ↑ 875% |
Brokerage commentary & target prices:
| Broker | Rating | Target Price (₹) | Comment |
|---|---|---|---|
| Jefferies | Underperform | 700 | ARV muted; CDMO steady; $600 Mn capex for Vizag |
| Goldman Sachs | Sell | 775 | Generic FDF drove revenue; CDMO flat QoQ; margin +24.4% |
| DAM Capital | Buy | 1,083 | EBITDA in-line; CDMO traction; GM ~60%; strong OCF; low net debt |
Investment verdict for Laurus Labs: The stock offers a compelling growth story with strong profitability rebound. Verdict: Buy / Hold depending on risk appetite.
Investor Takeaway
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Regd Investment Adviser, notes that while Colgate faces demand slowdown, Laurus Labs has demonstrated strong execution and margin growth. Investors seeking stability may hold Colgate; those looking for growth can consider Laurus Labs. Discover more fact-based guidance at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
Related Queries on Stocks
- Why are FMCG volumes declining post GST rate revision?
- What makes CDMO businesses attractive in pharma?
- How can investors assess margin expansion sustainability?
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
